Help shape the future of high cholesterol treatment.

Be part of the Pulse-1 study

pulse-1

pulse-1

Can you participate?

You may be eligible to take part if you*:

- Are 18-70 years old
- Have a medical history of either:
  - Very high LDL-C levels, known as severe hypercholesterolemia

  or
  - Atherosclerotic cardiovascular disease (ASCVD) — e.g., heart attack, stroke, or a stenting or bypass procedure to open a blocked blood vessel
- Have LDL-C levels that remain too high even after taking available LDL-C-lowering medicines (such as statins and/or PCSK9 inhibitors)
  - In some cases, people cannot take these medicines due to side effects or they do not have access to these medicines.
  - If this is the case, you may still be able to take part in the study.

*Additional eligibility criteria apply

About the Pulse-1 study

The Pulse-1 study is a Phase 1b clinical trial enrolling people who are at high risk of serious cardiovascular events, such as heart attack or stroke, due to high cholesterol levels.

The Pulse-1 study will help determine if a single dose of an investigational medicine, called VERVE-201, can safely reduce low-density lipoprotein cholesterol (LDL-C) in people whose LDL-C remains high even after taking currently available medicines.

About the investigational medicine

VERVE-201, the investigational gene editing medicine, is given as a single intravenous (IV) infusion into a vein in the arm. VERVE-201 is designed to turn off a gene called *ANGPTL3* in the liver. Other medicines that block ANGPTL3 activity have been shown to be safe and effective for lowering LDL-C. VERVE-201 has the potential to lower LDL-C levels for many years after a single dose.

What will the Pulse-1 study involve?

Up to 36 people in several countries will take part in the Pulse-1 study. Participants will be involved in the trial for up to one year after receiving VERVE-201. After the study is over, participants are expected to join a long-term follow-up study to help researchers understand the safety of VERVE-201 over a longer period. The study doctor will share the details of this study with you.

The Pulse-1 study has three periods:

1 Screening Period (up to three months)

You will attend screening appointments to determine your eligibility for the clinical trial. Several tests will be performed during this time, including taking blood samples and performing physical examinations.

- You will visit the study center twice to determine if you are eligible and whether the trial is right for you. If you are eligible, you will have the option to join the trial.
- The screening visits need to occur within a three month time period.

---

2 Study Treatment Period (about two days)

If you qualify and decide to participate, the study treatment period will involve a stay of approximately two days/one night at the study center, during which:

- You will receive a single dose of VERVE-201 as an intravenous (IV) infusion into a vein in your arm.
- During your stay at the study center, the study team will monitor your health and conduct assessments similar to the screening period to check how well you tolerate VERVE-201. If needed, your stay may be extended for additional monitoring.

---

3 Follow-up Period (about one year)

- There will be up to 11 follow-up visits over 1 year after receiving VERVE-201 to continue to monitor your health, including an end-of-study visit.
- After the end-of-study visit, you will continue to participate in the long-term follow-up study to monitor your safety and cholesterol levels. Some of these visits can be done from home.

Why might you participate?

By taking part in the Pulse-1 study, you will be contributing to the development of a potential new medicine that may help you and other people with high LDL-C, perhaps including family members, in the future. Study participants will receive VERVE-201, which may permanently reduce LDL-C levels. However, it is important to note that the safety and effectiveness of VERVE-201 is still being studied.

What is LDL-C, and why does it matter?

High LDL-C (low-density lipoprotein cholesterol) circulating in the blood is a major cause of atherosclerotic cardiovascular disease (ASCVD). ASCVD is a general term for conditions caused by cholesterol plaque buildup. If the plaque buildup becomes severe, it can restrict blood flow and lead to serious events such as a heart attack or stroke.

One of the best ways to reduce the risk of events like heart attack and stroke is to lower the level of LDL-C in the blood to medically recommended goals. Some people have LDL-C that remains higher than their goal even after making lifestyle changes and taking currently available cholesterol-lowering medicines. These individuals are at higher risk compared with patients who achieve these goals.

What else do you need to know about the Pulse-1 study?

The study team will explain the possible benefits and risks of participating in the Pulse-1 study.

You will be reimbursed for your time participating in this study.



You will be reimbursed for travel or other expenses during participation.

VERVE-201 and trial-related tests are provided at no cost for study participants.

A team of study doctors and nurses will monitor your health carefully during the trial.

The study has been cleared by an Institutional Review Board/Ethics Committee and national health authority, which protects the participants' rights, safety, and well-being.

pulse-1

How do you get more information?

To learn more, please visit
the study website at

pulse1study.com

Study participation is voluntary.
You are not obligated to take part
in the study by contacting us.